Trial Profile
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2019
Price :
$35
*
At a glance
- Drugs Tesevatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Exelixis
- 23 Feb 2010 Actual end date changed from Apr 2009 to Nov 2007 as reported by ClinicalTrials.gov.
- 16 Feb 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 16 Feb 2010 Actual patient number (41) added as reported by ClinicalTrials.gov.